PS/Cell Line | FAB (Immunophenotype) | Cytogenetics | 1B Gene Expression | Mean ED50 (± S.E.M.) of CD-160130 |
---|---|---|---|---|
Arbitrary Units | μM | |||
Myeloid primary samples and cell lines | ||||
AML-1 (Pillozzi et al., 2007) | AML-M4 (CD13+, CD33+, CD14+, CD11b+, CD34+) | UNK | 0.92 (1A: 12.20) | 20% maximum killing at 50 |
AML-2 (Pillozzi et al., 2007) | AML-M1 (CD13+, CD34+, HLDRA+) | Complex | 68.10 (1A: 18) | 40.4 ± 11.2 |
KG-1 | AML-M6 (CD34+, CD15+, Cd13+, HLA A30+, A31+, B35+) | Complex (Pelliccia et al., 2012) | 0.62 (1A: 24.76) | 7.6 ± 0.55 |
FLG 29.1 | AML-M5 (CD9+, CD13+, CD32+, CD42b+, CD51+, CD54+, CD44+, CD61+, CD45+, CD31+) | polyploidy, 3p+ | 3413 (1A: 1086) | 3.48 ± 0.88 |
HL60 | AML-M2 (Dalton et al., 1988) (CD3−, CD13+, CD14−, CD15+, CD19−, CD33+, HLA-DR−) | Pseudodiploid | 94.70 (1A: 13.70) | 6.65 ± 0.26 |
NB4 | AML-M3 (CD3−, CD4+, CD11b−, CD13+, CD14-, CD15+, CD19-, CD33+, CD34−, CD38+, HLA-DR−) | t(15;17)(q22;q11-12) | 196.72 (1A: 80.44) | 7.02 ± 0.31 |
Lymphoid primary samples and cell lines | ||||
B-ALL-1 | L2 (early B) (CD34+, CD33+, CALLA+) | t(8;14) | 6.68 (1A: 0.03)a | 5.6 ± 1.5 |
T-ALL-1 | L2 (T) (aberrant expression of CD34, CD117, and CD13) | UNK | 5.11 (1A: 0.76)b | 0.6 ± 0.2 |
REH | pro-B-ALL (CD3−, CD10+, CD13−, CD19+, CD34−, CD37−, CD38+, cyCD79a+, CD80−, CD138+, HLA-DR+, sm/cyIgG−, sm/cyIgM−, sm/cykappa−, sm/cylambda−) | t(12; 21)(p13;q22) | 120 (1A: 6.5) | 6.66 ± 0.22 |
697 | pre-B-ALL (CD3−, CD10+, CD13−, CD19+, CD34−, CD37−, CD38+, CD80−, HLA-DR+, sm/cyIgG−, smIgM−, cyIgM+, sm/cykappa−, sm/cylambda−) | t(1;19) | 1200 (1A:85) | 3.78 ± 0.37 |
RS | pre-B-ALL-L2 (HLA DR+, CD9+, CD24+) | t(4;11)(q21; q23) and i(7q) | 0.16 (1A: 0.005) | 7.0 ± 0.2 |
B-ALL, acute B-lymphoid leukemia primary sample; FAB, French-American-British; PS, primary sample; T-ALL, acute T-lymphoid leukemia primary sample; UNK, unknown; 1A, KCNH2a; 1B, KCNH2b.
↵a 1A and 1B values were average expression of a cohort of BCP-ALL patients.
↵b 1A and 1B values were average expression of a cohort of T-ALL patients.